Psychedelics
October 1, 2026
David S. Mathai, Brian Pilecki, Hadi Zaki et al.
In 2019, the U.S. Food and Drug Administration (FDA) approved a patented formulation and delivery method of esketamine, the S-enantiomer of ketamine, for patients with treatment-resistant depression (TRD). While ketamine-based treatments share similarities with serotonin 2 A receptor-mediated “classic psychedelics” like psilocybin regarding subjective drug effects and stimulation of...
Journal of Neuroendocrinology
October 1, 2026
Cristian Ferreira Corona, Felipe Alves Alencar Lima, Jessica Sabrina Canedo da Silva Sumensse et al.
Abstract Human binge eating disorder is characterized by recurrent episodes of excessive food consumption accompanied by loss of control and is strongly associated with alterations in reward processing and emotional regulation. Ayahuasca, a psychoactive botanical preparation traditionally used in Amazonian medicine, has been shown to modulate serotonergic signaling and reward‐related behaviors...
Frontiers in Pharmacology
September 30, 2026
Kacper Żełabowski, Tomasz Wieczorek, Adam Hamed
Stroboscopic light stimulation (SLS) and psilocybin each induce altered states whose phenomenology and neurophysiology partly overlap, including posterior alpha-band changes and visual imagery. The two states engage the alpha band through different operations - pharmacological suppression under psilocybin and frequency-selective visual drive under SLS. We formalize their possible interaction...
Translational Psychiatry
September 28, 2026
Johan Saelens, Franziska Stadler, Victoria Forschauer et al.
Obsessive-compulsive disorder (OCD) is a highly debilitating and often chronic condition. A large percentage of patients do not respond to first-line treatments with selective serotonin reuptake inhibitors (SSRIs) or cognitive behavioral therapy (CBT), underscoring the need for novel therapeutic approaches. In this context, promising innovative treatments have recently emerged for OCD; these...
International Journal of Innovative Technologies in Social Science
September 28, 2026
Klaudia Karolina Wójcik, Michal Kieres, Krzysztof Sebastian Habirek et al.
The article aims to compare receptor mechanisms related to neurotransmitters for some of the most widely used psychoactive substances - amphetamine, cocaine, ecstasy (MDMA), and psilocybin - and to link these mechanisms to cardiovascular effects, thermoregulation, and neurotoxicity. The review is based mainly on in vitro studies on transporters and receptors, animal models, and controlled...
Industrial Psychiatry Journal
September 25, 2026
Julio Torales, Marcelo O’Higgins, Iván Barrios et al.
ABSTRACT: Ayahuasca, a traditional Amazonian brew containing N,N-dimethyltryptamine (DMT) and β-carboline monoamine oxidase inhibitors, has expanded globally beyond Indigenous ceremonial systems. While acute visionary and psychotomimetic effects are expected and culturally integrated in ritual contexts, concerns have emerged about persistent psychotic symptoms in vulnerable individuals. This...
Frontiers in Psychiatry
September 24, 2026
Franziska Stadler, Johan Saelens, Ioline D. Henter et al.
Background: The past few decades have seen a revived interest in psychedelic-assisted and ketamine-assisted therapy for mental health disorders, but data concerning the acute, subacute, and long-term effects of serotonergic psychedelics on cognitive functioning are scarce. This international, online study (N = 759) sought to investigate the potential acute, subacute, and long-term effects of...
Clinical Neuropsychopharmacology and Addiction
September 24, 2026
Giacomo D’andrea, Antonio Inserra, Andrea Miuli et al.
While psychedelic experiences are often reported as positive, adverse psychological reactions can occur. We present the case of a 19-year-old Caucasian male who presented to the ER with suicidal thoughts after taking lysergic acid diethylamide (LSD) alone. He was diagnosed with anxious state associated with panic attacks, and suicidal thoughts without ideation or behaviors. He was admitted to...
Molecules
September 23, 2026
Aylín R. Tabal-Robles, María Eva González-Trujano, Gabriel Fernando Moreno-Pérez et al.
The genus Psilocybe has been characterized by central nervous system (CNS) effects and as a source of therapeutic drugs such as the alkaloids psilocybin and psilocin—secondary metabolites that produce rapid anxiolytic and antidepressant effects in preclinical and clinical studies. Furthermore, these mushrooms also contain bioactive primary metabolites, for example, the interesting case of...
Journal of Psychopharmacology
September 22, 2026
Maria Niedernhuber, Dila Suay, Bigna Lenggenhager et al.
BACKGROUND: Psychoactive serotonin 5-HT2A receptor agonists are potent modulators of awareness. Influential theories propose that psychedelics alter whole-brain dynamics by increasing neural signal diversity and dynamic flexibility. Beyond temporal variability, it is an open question whether psychedelics impact the characteristics of transient neural state sequences themselves. AIMS: Our goal...